Search results for "PARKINSON DISEASE"
showing 10 items of 223 documents
Melatonin levels in Parkinson's disease: Drug therapy versus electrical stimulation of the internal globus pallidus
1997
The objective of our work was to measure plasma melatonin levels in patients with Parkinson's Disease (PD) following electrical stimulation of the internal globus pallidus (GPi), and to compare these levels with groups of PD patients under drug therapy and healthy controls. The levels of melatonin were measured twice daily at 1000 and 1200. The GPi stimulation at 130 Hz lowered melatonin levels, while no changes were observed in the absence of stimulation. The melatonin levels from healthy subjects were lower than those observed in PD patients. The melatonin levels from PD patients under drug therapy were also measured during the night (2000-2400-0400) and at 0800 in order to observe their …
Memory for time intervals is impaired in left hemi-Parkinson patients.
2004
The basal ganglia have been proposed as one of the neural correlates of timekeeping functions. Both encoding and memory retrieval components for time perception are impaired in Parkinson's disease (PD). The aim of our study was to investigate in hemi-Parkinsonian patients the existence of a specific alteration in memory for time depending on the affected side, to better understand the contribution of the left or right basal ganglia circuits in different components of time perception. Right and left hemi-PD patients performed a time reproduction task in which they were required to reproduce in the same session short (5 s) and long (15 s) time intervals, in off- and on-therapy condition. Whil…
Periodontal health in a population with Parkinson's disease in Spain: a cross-sectional study.
2022
Background: The aim of this research is to evaluate the periodontal health of patients with Parkinson Disease (PD) in a Spanish cohort. Material and Methods: A cross-sectional study was performed on 104 patients with PD (mean age: 66.19+9.3 years) and 106 controls (mean age: 59.26+14.11 years). A pre-designed clinical protocol was implemented, which included a standardized epidemiological index for periodontal disease (CPITN), clinical attachment loss (CAL), tooth-loss, full mouth plaque index (FMPI), and oral hygienic habits. Univariate descriptions and comparative analysis were performed. Results: The majority of PD patients presented good oral hygienic habits. There were no significant d…
Changes in Oxidative Stress Index and Lipid Peroxidation Product in the Brain of Rats with Lesion of Central Dopaminergic System after Propofol Admin…
2019
Propofol is a commonly used intravenous anesthetic agent with antioxidant properties. However, the effect of propofol on oxidative stress index (OSI) and lipid peroxidation in Parkinson’s disease is still unknown. The present study aimed to evaluate the effect of propofol on OSI and malondialdehyde (MDA) level in the selected brain regions of the rats with Parkinson’s disease (PD). 32 male Wistar rats were divided into four groups: I- control group, II- group with PD, III-control group with propofol, IV-PD group with propofol. 60mg/kg of propofol was given to the 8-weeks-old rats intraperitoneally, and the selected parts of the rats’ brains (frontal cortex, striatum, thalamus and hippocampu…
Changes in Oxidative Stress Index and Lipid Peroxidation Product in the Brain of Rats with Lesion of Central Dopaminergic System after Propofol Admin…
2019
Propofol is a commonly used intravenous anesthetic agent with antioxidant properties. However, the effect of propofol on oxidative stress index (OSI) and lipid peroxidation in Parkinson’s disease is still unknown. The present study aimed to evaluate the effect of propofol on OSI and malondialdehyde (MDA) level in the selected brain regions of the rats with Parkinson’s disease (PD). 32 male Wistar rats were divided into four groups: I- control group, II- group with PD, III-control group with propofol, IV-PD group with propofol. 60mg/kg of propofol was given to the 8-weeks-old rats intraperitoneally, and the selected parts of the rats’ brains (frontal cortex, striatum, thalamus and hippocampu…
Ethical challenges in cell-based interventions for neurological conditions: some lessons to be learnt from clinical transplantation trials in patient…
2009
No paradox, no progress: inverse cancer comorbidity in people with other complex diseases.
2011
Salvador Martínez [et al.]. 5 p., 2 tables and references.
PGC-1α: a master gene that is hard to master
2012
Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a transcriptional coactivator that favorably affects mitochondrial function. This concept is supported by an increasing amount of data including studies in PGC-1α gene-deleted mice, suggesting that PGC-1α is a rescue factor capable of boosting cell metabolism and promoting cell survival. However, this view has now been called into question by a recent study showing that adeno-associated virus-mediated PGC-1α overexpression causes overt cell degeneration in dopaminergic neurons. How is this to be understood, and can these seemingly conflicting findings tell us something about the role of PGC-1α in cell stress and in cont…
Practical importance of neuroprotection in Parkinson's disease.
2003
Consensus could be reached that there is overwhelming evidence of preclinical neuroprotection. However, the evidence of neuroprotection/neurorescue under clinical conditions is limited. Lessons from clinical trials designed to show neuroprotection (selegiline, amantadine, dopamine agonists) demonstrate that with the drugs available neuroprotection/neurorescue has to start as early as possible. A PET-controlled clinical trial with ropinirole shows that there seems to be a good chance for neuroprotection in the early phase of Parkinson's disease in patients treated from the very beginning of the disease while there is no such benefit in patients with a late start of a neuroprotective therapeu…